- The trend backdrop is active with a 20-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
MDP
TOR
Week ended 24 Jul 2026
Weekly Investor Report
Medexus Pharmaceuticals Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
5.04 CAD
-0.8%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 37.0% above the Trend Line and sits at 92.4% of its 52-week range. The latest completed week returned -0.8%, after a 20.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.
Setup score
73
out of 100
Latest Close
5.04 CAD
24 Jul 2026
1W Return
-0.8%
latest completed week
4W Return
20.0%
short-term follow-through
12W Return
25.7%
quarterly tape
Trend Breadth
51.9%
27 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- 2 reversal markers appear in the recent smart-money tape.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.8%
Latest completed week; four-week move 20.0%.
Indicator stack
74/88
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
5 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 37.0% above the Trend Line and sits at 92.4% of its 52-week range. The latest completed week returned -0.8%, after a 20.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9512-week average 0.96
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.95Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers
No recent accumulation markers. 2 reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 20.0% over four weeks, 25.7% over 12 weeks, and 77.5% over one year. The current trend has remained active for 20 consecutive weeks.
Performance by holding period
Active trend streak20 weeks
Active weeks in one year27
Trend breadth51.9%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.42Latest activity-pressure read.
Pressure change152.0%Four-week change in activity pressure.
Leadership39.10Latest relative-leadership reading.
RS change89.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 87%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value25/100Relative valuation strength. Underlying universe rank 76; rank 1 is best.
Quality77/100Profitability and accounting quality. Underlying universe rank 24; rank 1 is best.
Momentum85/100Medium-term price momentum. Underlying universe rank 16; rank 1 is best.
Growth17/100Revenue and earnings growth. Underlying universe rank 84; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1.6x Market value relative to trailing revenue.
- EV / EBITDA
- 13.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.1% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 54.8% Gross profit retained from each unit of revenue.
- Operating margin
- 5.9% Operating profit retained from revenue.
- Free-cash-flow margin
- 3.7% Free cash flow generated from revenue.
- Return on invested capital
- 6.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -8.3% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -82.5% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.2x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 5 relevant articles.
0 positive · 5 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-4.0%Distance below the 52-week high.
13-week volatility6.2%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher16 of 268 weeks finished lower.
Best week+22.4%Week of 3 Jul.
Worst week-2.9%Week of 20 Mar.
Latest week-0.8%Week of 24 Jul.
Shape of recent returns
Strong gains5
Modest gains11
Flat weeks2
Modest losses8
Sharp losses0
Recent vol6.2%13-week weekly-return volatility.
Base vol5.5%52-week weekly-return volatility.
Up/down split27/21Count of positive and negative weeks in the 52-week window.
Average skew4.6% / -2.9%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorCA Healthcare
4-week rank3 / 47
Group average-0.8%
Trend breadth38.3%
Trend38.3%active weekly trend signals
MD48.9%positive activity pressure
RS27.7%positive relative leadership
Four-week leaders
IndustryCA Drug Manufacturers - Specialty & Generic
4-week rank1 / 21
Group average-1.5%
Trend breadth38.1%
Trend38.1%active weekly trend signals
MD42.9%positive activity pressure
RS19.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape71/100
Trend, activity pressure, participation, and risk combine to a 71/100 tape read.
Indicator analysis87/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.95; 2 reversal markers Factors59/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 60; Small Cap Core rank 71 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 5 relevant articles.
What's Going On With Medexus Pharmaceuticals Inc Stock Wednesday? Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 5.04 CAD | -0.8% | 3.68 CAD | 2.76 CAD | 1.42 | 39.10 | 136.8K | On |
| 17 Jul 2026 | 5.08 CAD | -2.1% | 3.60 CAD | 2.74 CAD | 1.36 | 41.66 | 191.3K | On |
| 10 Jul 2026 | 5.19 CAD | 1.0% | 3.52 CAD | 2.72 CAD | 1.17 | 45.69 | 249.4K | On |
| 3 Jul 2026 | 5.14 CAD | 22.4% | 3.44 CAD | 2.70 CAD | 0.87 | 45.60 | 376.5K | On |
| 26 Jun 2026 | 4.20 CAD | 0.0% | 3.36 CAD | 2.68 CAD | 0.57 | 20.59 | 268.3K | On |
| 19 Jun 2026 | 4.20 CAD | 4.7% | 3.31 CAD | 2.66 CAD | 0.54 | 20.68 | 24.3K | On |
| 12 Jun 2026 | 4.01 CAD | 2.6% | 3.26 CAD | 2.64 CAD | 0.73 | 15.29 | 13.6K | On |
| 5 Jun 2026 | 3.91 CAD | 0.8% | 3.22 CAD | 2.62 CAD | 1.03 | 14.22 | 32.6K | On |
| 29 May 2026 | 3.88 CAD | -2.8% | 3.17 CAD | 2.61 CAD | 1.31 | 12.32 | 152.5K | On |
| 22 May 2026 | 3.99 CAD | -0.5% | 3.14 CAD | 2.59 CAD | 1.52 | 16.37 | 161.3K | On |
| 15 May 2026 | 4.01 CAD | -0.5% | 3.10 CAD | 2.57 CAD | 1.65 | 19.37 | 228.3K | On |
| 8 May 2026 | 4.03 CAD | 0.5% | 3.06 CAD | 2.56 CAD | 1.74 | 19.45 | 241.3K | On |
| 1 May 2026 | 4.01 CAD | 1.0% | 3.01 CAD | 2.54 CAD | 1.81 | 19.59 | 148.4K | On |
| 24 Apr 2026 | 3.97 CAD | 0.0% | 2.98 CAD | 2.52 CAD | 1.91 | 18.54 | 273.0K | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.